Welcome to our dedicated page for Curaleaf Hldgs news (Ticker: CURLF), a resource for investors and traders seeking the latest updates and insights on Curaleaf Hldgs stock.
Curaleaf Holdings, Inc. reports developments across its consumer cannabis business, including retail dispensary openings, medical and adult-use product brands, quarterly operating results, and international expansion. The company trades on the Toronto Stock Exchange as CURA and on OTCQX as CURLF.
Recurring updates cover brands such as Curaleaf, Select, Grassroots, Find, Dark Heart, Anthem, and Four 20 Pharma; U.S. dispensary activity; medical cannabis distribution in Germany and other international markets; share repurchase activity; board and shareholder matters; and regulatory topics affecting cannabis operations.
Curaleaf (OTCQX:CURLF, TSX:CURA) announced that, effective July 6, 2026, its Subordinate Voting Shares have resumed trading on the OTCQX Best Market under the symbol CURLF.
The change follows a 20-trading-day transition period under CURLD after a 1-for-3 reverse stock split. No shareholder action is required.
Curaleaf (OTCQX:CURLF, TSX:CURA) will report second quarter 2026 financial and operational results for the period ended June 30, 2026, after market close on August 5, 2026.
Management will host an earnings conference call and webcast at 5:00 p.m. ET, including prepared remarks and a Q&A session.
Curaleaf (OTCQX:CURLF) held its 2026 annual and special shareholders meeting via webcast on June 22, 2026, with 1,712,387,752 votes cast. Shareholders approved an amendment removing the automatic conversion feature of multiple voting shares, an option exchange program for up to 10,070,478 options, and a plan of arrangement to continue the company from British Columbia to Delaware. The amendment and arrangement received approval levels up to 100% within certain share classes, and all seven board nominees were elected with at least 97.156% support.
Curaleaf (OTCQX:CURLF, TSX:CURA) confirmed its previously announced 1-for-3 reverse stock split of subordinate voting shares will be effective June 5, 2026. Shares will continue trading on the TSX as CURA with new CUSIP 23126M300.
Outstanding subordinate voting shares will decline from 698,731,895 to about 232,910,632, with fractional shares rounded to the nearest whole share. Multiple voting shares will be consolidated on the same 1‑for‑3 basis to preserve relative rights.
Curaleaf (OTCQX:CURLF) will implement a 1-for-3 reverse stock split of its subordinate voting shares, effective on or about June 5, 2026, following TSX conditional approval.
The split is intended to raise the share price, support potential U.S. exchange uplisting, and broaden institutional and retail investor access.
Curaleaf (OTCQX: CURLF) opened two new Florida medical dispensaries in Jacksonville Beach and Fernandina Beach on May 8, 2026, raising its Florida store count to 73 and nationwide total to 165.
The locations offer Curaleaf and partner brands including Reef, Grassroots, Dark Heart, Anthem pre-rolls, and the new Select Briq 2. Grand opening events run May 8–9 (Jacksonville Beach) and May 15–16 (Fernandina Beach) with promotions, giveaways, and patient offers.
Curaleaf (OTCQX: CURLF) reported Q1 2026 results: net revenue $324.2M (up 6% YoY), international revenue $47.2M (up 35% YoY), gross profit margin 49%, net income $70.1M and adjusted EBITDA $63.4M (19.6% margin). The company completed a buyout of Four20 Pharma to 100% ownership and closed $500M senior secured notes to refinance prior debt.
Cash was $106.1M, debt net $565.1M, and weighted average shares were 775.4M.
Curaleaf (OTCQX: CURLF) announced on May 1, 2026 the appointment of Torsten Greif to its Board of Directors. Greif is a founder of Four 20 Pharma, Curaleaf's German brand, and brings expertise in cannabis cultivation, regulatory strategy, and EU-GMP medical cannabis distribution as Curaleaf expands in Europe.
Curaleaf (OTCQX: CURLF) completed the buyout of the remaining 45% stake in Four 20 Pharma GmbH on April 30, 2026, making Four 20 a fully owned Curaleaf subsidiary.
Four 20 Pharma is EU-GMP and GDP licensed in Germany; the purchase strengthens Curaleaf's vertical, seed-to-patient supply chain and supports further European brand expansion.
Curaleaf (OTCQX: CURLF) will hold its Annual and Special Meeting on June 22, 2026 at 9:00 a.m. ET in a virtual format. Shareholders of record as of May 5, 2026 may vote.
Agenda items include director elections, auditor appointment, continuation of the 2018 LTIP, an MVS sunset amendment, an Option/RSU exchange (options tied to >=US$5.00), and the previously announced BC-to-Delaware continuation arrangement. A management information circular will be filed and mailed around May 12, 2026 via SEDAR+ and EDGAR. The company will use notice-and-access delivery for meeting materials.